Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Relationship between semiquantitative 18F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma
Published in: Scientific Reports
Access to document
10.1038/s41598-019-47453-5
document
Semiquantitative 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) parameters have been proposed as prognostic markers in classical Hodgkin lymphoma (cHL). In non-Hodgkin lymphoma necrosis as assessed by 18F-FDG PET or computed tomography (CT) (necrosisvisual) correlates with an adverse prognosis. We investigated whether semiquantitative 18F-FDG PET metrics correlate with necrosisvisual, determined the incidence of necrosisvisual and explored the prognostic impact of these factors in cHL. From 87 cHL cases treated with ABVD, (escalated) BEACOPP or CHOP chemotherapy between 2010 and 2017, 71 had both a NEDPAS/EARL accredited 18F-FDG PET and...
X U Kahle, F M Montes de Jesus, T C Kwee, T van Meerten, A Diepstra, S Rosati, A W J M Glaudemans, W Noordzij, W J Plattel, M Nijland
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
Published in: Nature Communications
Access to document
10.1038/s41467-018-08013-z
document
CD47 is a prominent new target in cancer immunotherapy, with antagonistic antibodies currently being evaluated in clinical trials. For effective evaluation of this strategy it is crucial to identify which patients are suited for CD47-targeted therapy. In this respect, expression of the pro-phagocytic signal SLAMF7 on both macrophages and cancer cells was recently reported to be a requisite for CD47 antibody-mediated phagocytosis. Here, we demonstrate that in fact SLAMF7 expression on cancer cells is not required and does not impact on CD47 antibody therapy. Moreover, SLAMF7 also does...
Yuan He, Renee Bouwstra, Valerie R. Wiersma, Mathilde de Jong, Harm Jan Lourens, Rudolf Fehrmann, Marco de Bruyn, Emanuele Ammatuna, Gerwin Huls, Tom van Meerten, Edwin Bremer
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting
Published in: Annals of Oncology
Access to document
10.1093/annonc/mdy482
document
H. T. van der Galien, M. Hoogendoorn, R. E. Kibbelaar, T. van Meerten, R. S. van Rijn
Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?
Published in: Molecular and Cellular Oncology
Access to document
10.1080/23723556.2019.1600349
document
Innate immune checkpoint CD47 has emerged as a prominent target for cancer immunotherapy and defining biomarkers predictive of response will be a crucial step towards clinical implementation. Hereto, we investigated the importance of a previously reported requisite for SLAM family member 7(SLAMF7) expression on cancer cell phagocytosis for effective CD47 antibody therapy.
Renee Bouwstra, Tom van Meerten, Edwin Bremer
Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis
Published in: Critical Reviews in Oncology/Hematology
Access to document
10.1016/j.critrevonc.2018.09.007
document
Introduction and aim: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after solid organ and hematopoietic stem cell transplantation, associated with significant morbidity and mortality. In this systematic review we evaluated the clinical performance of advanced imaging modalities at diagnosis and treatment response evaluation of PTLD patients after solid organ and hematopoietic stem cell transplantation. Methods: We have carried out a literature search until December 15, 2017 using PubMed/Medline, Embase, “Web of Science” and Cochrane Library databases concerning the performance of computed tomography (CT), magnetic resonance imaging (MRI)...
F M Montes de Jesus, T C Kwee, M Nijland, X U Kahle, G Huls, R A J O Dierckx, T van Meerten, O Gheysens, D Dierickx, V Vergote, W Noordzij, A W J M Glaudemans